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Objectives: Cardiac allograft vasculopathy remains a major cause of mortality after cardiac transplantation.
Percutaneous revascularization has become the mainstay of therapy given the poor historical outcomes with sur-
gery. Outcomes following surgical revascularization are evaluated to determine whether surgery remains a viable
therapeutic option.
Methods: A retrospective analysis was performed of 13 heart transplant recipients who had cardiac allograft
vasculopathy requiring coronary artery bypass grafting with or without adjunctive percutaneous coronary inter-
vention for revascularization from 1999 to 2008.
Results: Thirteen patients had 14 coronary artery bypass grafting procedures at 141 66 months after transplan-
tation. The average number of grafts was 2.3. Eight were performed without cardiopulmonary bypass, of which 5
were approached via left thoracotomy and the remainder via repeat sternotomy. One patient had renal failure and
a cerebrovascular accident. Percutaneous coronary intervention before or after coronary artery bypass grafting
was required in 3 patients. There were no perioperative mortalities. At mean follow-up of 39  36 months, 3
patients have died, 2 from progressive cardiac allograft vasculopathy and 1 from lung cancer. Kaplan-Meier
survival for this group of patients was 92%, 83%, and 83% at 1, 5, and 7 years, respectively.
Conclusions: Surgical revascularization for cardiac allograft vasculopathy remains a viable treatment option for
appropriate patients andmay be performed safely with goodmedium-term outcomes. However, patients remain at
risk for disease progression and may require percutaneous or surgical reintervention.
CARDIOTHORACIC TRANSPLANTATIONDespite recent advances in immunosuppression, cardiac
allograft vasculopathy (CAV) remains a major cause of mor-
tality after the first year of transplantation, with an incidence
between 30% and 50% at 5 years.1 The mainstays of non-
pharmacologic treatment options include percutaneous coro-
nary intervention (PCI), coronary artery bypass grafting
(CABG), and retransplantation. Although outcomes follow-
ing retransplantation for this group of patients have im-
proved, the scarcity of suitable donor organs remains
a significant limitation, and consequently this option is usu-
ally reserved for patients with disease progression despite
revascularization or those with diffuse coronary involve-
ment.2 PCI has become the primary treatment modality for
heart transplant recipients with CAV and is associated with
excellent short-term results. Its applicability is limited, how-
ever, considering the diffuse and heterogeneous coronary
involvement typically seen in patients with CAV.3
Historically, CABG has been associated with poor surgical
From the Division of Cardiothoracic Transplantation, Heart, Lung & Esophageal
Surgery Institute,a and The Cardiovascular Institute,b University of Pittsburgh
Medical Center, Pittsburgh, Pa.
Received for publication Aug 28, 2008; revisions received Dec 26, 2008; accepted for
publication Feb 3, 2009.
Address for reprints: Jay K. Bhama, MD, 200 Lothrop St, Suite C-900, Heart, Lung &
Esophageal Surgery Institute, Division of Cardiothoracic Transplantation, Univer-
sity of Pittsburgh Medical Center, Pittsburgh, PA 15213 (E-mail: bhamajk@
upmc.edu).
J Thorac Cardiovasc Surg 2009;137:1488-92
0022-5223/$36.00
Copyright  2009 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2009.02.0261488 The Journal of Thoracic and Cardiovascular Suoutcomes with early mortality rates in excess of 30%.4 How-
ever, little recent data exist in the literature regarding the out-
comes ofCABG in patientswithCAV.Wepresent the largest
single-center experience with surgical revascularization for
CAV and report short-term and midterm outcomes.
METHODS
Patients
Approval was obtained from the University of PittsburghMedical Center
Total Quality Control council. Since the inception of our heart transplant
program in 1980 through 2008, a total of 1175 patients have had orthotopic
cardiac transplantation. A retrospective reviewwas performed of 13 patients
who had CAV post–heart transplantation and were treated with surgical re-
vascularization from 1999 to 2008. All patients were evaluated for PCI prior
to surgical intervention, and 3 patients had PCI either before or after surgical
revascularization. A detailed chart review was then performed for each
patient to collect demographic, procedural, and outcome data. Follow-up
was complete in all patients.
Immunosuppression and Infection Prophylaxis
The immunosuppressive regimen evolved over time with initial empha-
sis on the use of cyclosporine with either steroids or aziothioprine. In 1993,
we began routinely using tacrolimus instead of cyclosporine. Our current
protocol also uses mycophenolate mofetil maintenance therapy, which
was introduced routinely beginning in 1999. Induction therapy with antith-
ymocyte globulin was used selectively in some cases. All patients received
Pneumocystis carinii prophylaxis with trimethoprim/sulfamethoxazole,
cytomegalovirus prophylaxis with valacyclovir or valgancyclovir, and
Clostridium difficile prophylaxis with oral metronidazole.
Procedures
PCI was considered the primary modality for therapy, and all patients
were evaluated for suitability by an interventional cardiologist. PCI wasrgery c June 2009
Bhama et al Cardiothoracic Transplantation
T
XAbbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CAV ¼ cardiac allograft vasculopathy
CPB ¼ cardiopulmonary bypass
PCI ¼ percutaneous coronary intervention
performed utilizing standard techniques, including angioplasty and/or stent
deployment along with anticoagulation and antiplatelet pharmacotherapy.
Procedural success was defined as residual diameter stenosis of<50%. Pa-
tients were treated with aspirin indefinitely and clopidogrel for 6 to 12
months following intervention based upon the type of procedure performed.
Follow-up angiograms were not performed routinely due to the risk of con-
trast nephropathy. Individuals with symptoms or a noninvasive stress test
suggestive of ischemia or worsening left ventricular function had angiogra-
phy. Restenosis was defined as>50% narrowing of the target lesion by
visual estimation.
Surgical revascularization was favored in patients with multivessel in-
volvement or in the presence of single-vessel disease not amenable to PCI
due to technical limitations or the presence of active ischemia or anginal
symptoms. Standard CABG was performed via midsternotomy utilizing
right atrial–aortic cardiopulmonary bypass (CPB) with antegrade, mild
hypothermia, aortic crossclamping, and antegrade/retrograde cold blood
cardioplegia. Alternate approaches included revascularization via left thora-
cotomy or midsternotomy with off-pump CABG techniques. A left thora-
cotomy approach was favored for patients with single- or double-vessel
disease isolated to the anterior and lateral territories.
Angiographic Classification of Lesions
Coronary angiograms were reviewed and lesions were classified accord-
ing to the system of Gao and colleagues5 (Figure 1). Type A lesions were
discrete and tubular or had multiple stenoses. Type B1 lesions were abrupt
in onset with distal diffuse concentric narrowing and obliteration. Type B2
lesions had gradual, concentric tapering with distal portions retaining some
residual lumen. Type C lesions had narrowed irregular distal branches with
terminations often nontapered and squared off, ending abruptly. Revascu-
larization was required in 1 patient with catheter-induced dissection of the
left main coronary artery; this was classified as type A.
Statistics
Descriptive statistics are reported as mean standard deviation. Survival
was calculated according to the method of Kaplan and Meier with death as
the primary end point.
RESULTS
Demographic data for this group of patients are listed in
Table 1. The average age at intervention was 57  15 years
(range 20–75). The mean interval between transplantation
and CABG was 147  75 months (range 15–251 months).
Most patients had preserved left ventricular function and
presented with angina. Triple-vessel disease was the
predominant form of CAV treated with revascularization
[5/13 (38%)].
Procedural data for the 13 patients who had CABG are
listed in Table 2. The average number of grafts per patients
was 2.3. Off-pump techniques were utilized in 8 cases
(57%) with 5 cases (36%) approached via a left thoracot-
omy. The left internal thoracic artery was used in 11/13The Journal of Thoracic and C(85%) patients. Type C angiographic grade lesions
accounted for 31% of lesions bypassed. Three patients in
this group had multiple interventions including PCI per-
formed before, after, or as an adjunct to CABG. Specific
details regarding the location of lesions and order of inter-
ventions are delineated in Table 3. One patient required
repeat CABG for a myocardial infarction following PCI.
Five of the 6 patients who had surveillance angiography
had patent bypass grafts. One patient required PCI subse-
quent to surveillance angiography for a diseased saphenous
vein graft.
FIGURE 1. Gao classification system for CAV. Modified from Gao and
colleagues.5
TABLE 1. Demographic data for patients having surgical revascu-
larization for the treatment of CAV
Variable Value (n ¼ 13)
Mean age at intervention (y) 57  15
Male genderMale 11
Diabetes 5
Hypertension 11
Dyslipidemia 8
Mean interval to intervention (mo) 147  75
LVEF (%) at intervention 53  7
Presenting symptom
Angina 8
Asymptomatic 4
CHF 1
Arrhythmia 0
Preintervention myocardial infarction 2
Severity of coronary disease
Single vessel 4
Double vessel 4
Triple vessel 5
CABG, Coronary artery bypass graft; CAV, cardiac allograft vasculopathy; CHF,
congestive heart failure; LVEF, left ventricular ejection fraction; PCI, percutaneous
coronary interventions.ardiovascular Surgery c Volume 137, Number 6 1489
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listed in Table 4. No patient had low cardiac output or re-
quired reoperation for bleeding. There was no perioperative
mortality. At a mean follow-up of 39  36 months (range
0.3–110 months) after CABG, 10/13 (77%) patients are
alive. Two patients died of progressive CAV and 1 from
lung cancer. Kaplan-Meier survival for this group of patients
was 92%, 83%, and 83% at 1, 5, and 7 years, respectively
(Figure 2).
DISCUSSION
In this study, we present early to midterm outcomes with
CABG for the treatment of CAV in 13 patients demonstrat-
ing that surgical management remains a viable option for
selected patients. CAV remains the nemesis of cardiac trans-
plant recipients surviving beyond the first year of transplant.
In most patients, CAV is an insidious process that may occur
without warning, resulting in silent myocardial infarction,
arrhythmia, or sudden death. Advances in our understanding
regarding CAV have focused largely upon understanding its
pathogenesis and methods by which to attenuate its progres-
TABLE 2. Procedural data for 13 patients having CABG for the
treatment of CAV
Variable Value
Total number of procedures 14*
Total number of lesions bypassed 32
Angiographic grade of lesions bypassed
A 7
B1 7
B2 4
C 10
Unknown 4
Surgical approach
On-pumpþ repeat sternotomy 6
Off-pumpþ repeat sternotomy 3
Off-pumpþ left thoracotomy 5
Number of grafts (average) 2.3
1 4
2 4
3 4
4 2
Proportion LITA utilization 11
CABG, Coronary artery bypass graft; CAV, cardiac allograft vasculopathy; LITA, left
internal thoracic artery. *One patient had 2 operations.sion. Preventative strategies are directed toward limiting
both cellular and humoral rejection during the first year post-
transplantation by optimization of immunosuppressive ther-
apy. Other preventative strategies include treatment of
nonimmunologic factors such as hyperlipidemia, hyperten-
sion, and cytomegalovirus infection. Novel modalities for
pharmacologic therapy include immunosuppressive agents
such as sirolimus or everolimus, both of which have demon-
strated improvements in disease progression but have not
significantly impacted overall survival.6-8 Despite these
measures, CAV continues to account for approximately
30% to 50% of deaths in cardiac transplant recipients.1
The primary modalities of treatment used in the manage-
ment of advanced CAV include PCI, surgical revasculariza-
tion, and retransplantation. Selection among thesemodalities
depends primarily upon the extent of disease. PCI andCABG
are generally reserved for those with focal proximal disease;
formost patients with diffuse coronary involvement, PCI and
CABG remain ineffective due to inadequate anatomic fea-
tures and poor distal vessel quality. For these patients,
retransplantation remains the primarymodality for treatment.
Although earlier reports noted that the 1-year mortality for
patients retransplanted for CAV was 30% to 40%, more
recent studies have demonstrated that in otherwise healthy
patients, retransplantationmay be carried out safelywith out-
comes that are similar to primary transplantation.3 There had
been a transient interest in transmyocardial laser revascular-
ization after initial case reports, but late follow-up has failed
to demonstrate sustained benefits.9,10
In this study, which we believe to be the largest single-
center experience described in the literature, we demonstrate
significant improvement in early survival following surgical
management as compared with previous studies (Table 5).
However, the literature regarding standard surgical revascu-
larization for CAV is relatively limited, with only 3 previ-
ously published series. A multi-institutional study by Halle
and associates11 reported the outcomes of 12 patients who
had CABG. Four patients died perioperatively due to ven-
tricular failure in 3 patients and bleeding in 1 patient. Distal
arteriopathy (type C) on the preoperative angiogram was
noted in 80% of patients who died versus 14% of survivors
and was felt to be a significant predictor of increased mortal-
ity. This study did not delineate surgical considerationsTABLE 3. Multiple interventions in patients who had combined PCI and CABG for treatment of CAV
Patient 1st intervention 2nd intervention 3rd intervention 4th intervention 5th intervention
1 CX1, CX2 LAD, D
PCI CABG
2 CX and LAD CX and LAD LAD CX
PCI PCI CABG PCI*
3 LAD CX and RCA LM and CX CX SVG
CABG PCI* PCI CABG PCI
CABG,Coronary artery bypass grafting;CAV, cardiac allograft vasculopathy;CX, circumflex;D, diagonal; LAD, left anterior descending; LM, left main; RCA, right coronary artery;
PCI, percutaneous coronary intervention; SVG, saphenous vein graft. *Planned intervention.
1490 The Journal of Thoracic and Cardiovascular Surgery c June 2009
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evant to surgical outcomes. Parry and colleagues12 described
5 patients who had CABG; 2 died perioperatively, 1 from
left ventricular failure and the other from acute rejection.
All 5 cases were done with normothermic CPB with use of
the left internal thoracic artery. Musci and coworkers13 re-
ported their results with CABG in 7 patients with CAV
with 3 perioperative deaths. All patients who died had dif-
fuse, distal arterial disease (type C) and emergency surgery.
Evaluation of the distribution and type of lesions for
which CABG was performed (Table 2) revealed that 10/32
lesions bypassed (31%) were type C, which in previous re-
ports has not been felt to be amenable to surgical revascular-
ization. In our experience, these patients had similar early
and midterm outcomes following surgery as patients with
lesser degrees of coronary disease. We believe that this
may be explained in part by the observation that many of
these patients had combinations of lesions at different
stages, and the most advanced lesion was the one used to
classify the respective target vessel. For example, a vessel
with diffuse disease (type C) might be accompanied by
a proximal 80% stenosis (type A). Although this would be
classified as a type C lesion, if the artery was of adequate
size for revascularization, we considered the patient an ac-
ceptable candidate for surgery. This was the case in the 3 pa-
tients who had isolated bypass of the left anterior descending
artery for type C disease. In addition, we also noted that sev-
eral patients had type C disease in 1 territory but lesser dis-
ease (type A or B) in another territory. This was the case for
the other 7 patients with type C disease who had multivessel
revascularization. Therefore, the presence of hemodynami-
cally significant lesions, even if accompanied by type C dis-
ease, warranted revascularization if the vessel was deemed
of an adequate size (1.8 to 2 mm). Although it is encouraging
that all of these patients did well, we are not suggesting that
surgical revascularization is always the correct answer for
patients with type C disease. Clearly, careful patient selec-
tion is very important in achieving good outcomes, and mul-
TABLE 4. Postprocedural morbidity and survival data for 13 patients
having surgical revascularization for the treatment of CAV
Variable Value
Complication
ARF 1
CVA 1
Infection (sepsis, pneumonia, urine) 0
Return to OR for bleeding 0
Arrhythmia 0
Early mortality* 0
Late mortality
Cardiac 2
Noncardiac 1
ARF, Acute renal failure; CAV, cardiac allograft vasculopathy; CVA, cerebrovascular
accident; OR, operating room. *Within 30 days or during primary hospitalization.The Journal of Thoracic and Ctiple factors should be considered including the patient’s
overall physiologic and functional status, the presence of
concomitant renal dysfunction, coronary anatomy (size
and disease distribution), the likelihood of achieving com-
plete revascularization, and whether alternative surgical
approaches are applicable.
Our surgical strategy is unique in that we selectively uti-
lized off-pump techniques, avoiding CPB in the majority of
cases with the intent of preventing the potential deleterious
effect of CPB on end-organ function. Additionally, by utiliz-
ing a left thoracotomy incision for patients requiring limited
revascularization, a secondary sternotomy was avoided in
36% of cases. We believe that avoiding the inflammatory
cytokine activation and deleterious effect on the coagulation
cascade that typically accompanies redo cardiac surgery
may be a contributing factor to the improved outcomes ex-
perienced by these relatively high-risk patients.14
There are several limitations to this study, aside from its
retrospective nature. The limited number of patients and
strict patient selection criteria make it difficult to determine
the exact impact of the different surgical techniques on
postoperative outcome. Additionally, the study spanned
a 10-year period in which patients were treated with different
immunosuppressive regimens. Although this may have
potentially impacted the development of CAV and its
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FIGURE 2. Kaplan-Meier survival for patients having surgical revascular-
ization for the treatment of cardiac allograft vasculopathy.
TABLE 5. Review of the literature on surgical revascularization for
CAV including data regarding utilization of CPB and angiographic
lesion classification
Author (year)
Number
of patients
Off-pump
(%)
Type C
lesion
grade (%)
Early
mortality (%)*
Halle et al (1995)11 12 0 42 25
Parry et al (1996)12 5 0 0 40
Musci et al (1998)13 7 14 57 43
CAV, Cardiac allograft vasculopathy; CPB, cardiopulmonary bypass. *Within 30 days
or primary hospitalization.ardiovascular Surgery c Volume 137, Number 6 1491
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have impacted the quality of early surgical outcomes. Al-
though our results with surgical revascularization are en-
couraging, they should be interpreted with caution given
the limited angiographic follow-up in only 6 of 13 patients
(46%). Although our patients experienced excellent early
survival following surgical revascularization, adjunctive
PCI was required in 2 patients. These findings highlight
the insidious nature of CAV and demonstrate that although
CABG may be a durable solution, it clearly does not repre-
sent a cure for these patients.
In conclusion, we demonstrate improved early outcomes
following surgical revascularization for patients with CAV
as compared with previous reports. These results may be
related to a thorough preoperative assessment and the use
of alternative approaches including off-pump techniques
and the avoidance of secondary sternotomy, factors that
may play a significant role in preventing complications
including perioperative bleeding and renal deterioration.
Although surgical revascularization may not be suitable
for all patients with CAV, candidates with acceptable coro-
nary anatomy should not be denied surgery based upon the
risk of surgery itself. Rather, the decision to operate should
be based on the usual algorithms used in selecting candi-
dates for reoperative CABG. Close and frequent surveil-
lance is necessary, even after successful CABG, due to
the progressive nature of the disease and frequent need for
reintervention.
We acknowledge the editorial assistance of Shannon L. Wyszo-
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